Lipofor

Gemfibrozil, the active ingredient in Lipofor, is a fibrate presented as an oral tablet for oral use. It treats hypertriglyceridaemia and mixed dyslipidaemia in adults.

GNH USA supplies Lipofor as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Gemfibrozil acts on lipid metabolism pathways to correct abnormal triglyceride and cholesterol levels. - Hypertriglyceridaemia: lowers elevated triglyceride concentrations. - Mixed dyslipidaemia: reduces triglycerides and modestly raises HDL‑C, improving overall lipid profile. - Prevention of pancreatitis secondary to severe hypertriglyceridaemia: decreases the risk of pancreatitis by controlling triglyceride levels.

Gemfibrozil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, dyspepsia, abdominal pain, or diarrhea. - Headache: mild to moderate intensity. - Elevated liver enzymes: transient increases in ALT/AST. - Skin reactions: rash or pruritus. - Muscle pain: mild myalgia without weakness.

Serious or Rare Side Effects: - Myopathy or rhabdomyolysis, especially when combined with statins. - Severe hepatotoxicity: marked elevation of liver enzymes or hepatitis. - Acute pancreatitis. - Blood dyscrasias: leukopenia, thrombocytopenia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters. - Liver function monitoring: obtain baseline and periodic ALT/AST levels. - Renal function assessment: evaluate creatinine clearance, especially in the elderly. - Gallstone risk: consider history of biliary disease before use. - Hepatic impairment: avoid in patients with severe liver dysfunction. - Statin co‑therapy: review dosage and monitor for muscle toxicity. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Gemfibrozil interacts with several drug classes; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Statins (especially high‑dose simvastatin or atorvastatin): increased risk of myopathy. - Anticoagulants (warfarin): potentiation of anticoagulant effect, may raise INR. - Cyclosporine: heightened risk of hepatotoxicity and myopathy. - Oral contraceptives: may reduce contraceptive efficacy. - Dual fibrate therapy: elevated risk of liver and muscle toxicity.

Moderate Interactions (Monitor Closely): - Digoxin: possible increase in serum digoxin levels. - Beta‑blockers: may enhance bradycardic effects. - ACE inhibitors: monitor renal function and potassium levels.